. Regulation of prohormone convertase 1 (PC1) by thyroid hormone. Am J Physiol Endocrinol Metab 280: E160-E170, 2001.-The prohormone convertases (PCs) PC1 and PC2 are key enzymes capable of processing a variety of prohormones to their bioactive forms. In this study, we demonstrated that 6-n-propyl-2-thiouracil (PTU)-induced hypothyroidism stimulated, whereas triido-L-thyronine (T 3 )-induced hyperthyroidism suppressed, PC1 mRNA levels in the rat anterior pituitary. Using 5Ј deletions of the human PC1 (hPC1) promoter transiently transfected into GH3 (a somatotroph cell line) cells, we found that T 3 negatively regulated hPC1 promoter activity and that this regulation required the region from Ϫ82 to ϩ19 bp relative to the transcription start site. Electrophoretic mobility shift assays (EMSAs) using purified thyroid hormone receptor-␣1 (TR␣1) and retinoid X receptor-␤ (RXR␤) proteins and GH3 nuclear extracts demonstrated that the region from Ϫ10 to ϩ19 bp of the hPC1 promoter bound TR␣1 as both a monomer and a homodimer and bound TR␣1/RXR␤ as a heterodimer and multimer. EMSAs with oligonucleotides containing point mutations of the putative negative thyroid response elements (TREs) exhibited diminished homodimer and loss of multimer binding. We conclude that there are multiple novel TRE-like sequences in the hPC1 promoter located from Ϫ10 to ϩ19 bp. posttranslational processing; negative thyroid response ele-
posttranslational processing; negative thyroid response element; hypothyroidism; processing enzyme; pituitary; regulation; triiodo-L-thyronine PROHORMONE CONVERTASES (PCs), members of the mammalian family of the subtilisin-like endoproteases, are thought to be responsible for cleavage of many prohormones at paired basic residues to generate bioactive hormones (43, 55) . Among the seven members of the PC family recently cloned, PC1 and PC2 are specifically found in neural and endocrine cells equipped with a regulatory-secretory pathway (43, 55) . PC1 and PC2 process a variety of brain and pituitary prohormones, including proopiomelanocortin (POMC), prosomatostatin, provasopressin, proneurotensin, pro-thyrotropinreleasing hormone (TRH), and proenkephalin (33, 43) . The important role of PC1 and PC2 in hormonal biosynthesis has been elucidated by studies of mice lacking PC2 and of a patient with defective PC1. Mice with a PC2 knockout have absent proglucagon processing and impaired proinsulin processing, and they were hypoglycemic (10); proenkephalin processing was blocked (20) . The patient lacking PC1 had severe childhood-onset obesity, postprandial hypoglycemia, infertility, and low levels of ACTH and cortisol with elevated levels of POMC (16, 38) .
In the rat pituitary, PC1 is present primarily in the anterior lobe, with lower levels in the posterior and intermediate lobes, whereas PC2 is found predominantly in the intermediate lobe (44) . Rat intermediate lobe PC1, PC2, and POMC mRNA levels increased with treatment with the dopamine antagonist haloperidol and decreased with the dopamine agonist bromocriptine (2, 3, 6) . This regulation is likely to involve the intracellular cAMP pathway (17) . Limited studies of the regulation of processing enzymes by thyroid status have also been performed in the rat pituitary. Rats made hypothyroid by thyroidectomy or by 6-n-propyl-2-thiouracil (PTU) treatment had an increase in anterior pituitary PC1, PC2 (6) , and peptidylglycine ␣-amidating monooxygenase (PAM, a processing enzyme involved in amidation) mRNA levels (39) and a decrease in paired basic amino acid converting enzyme 4 (PACE4, a more ubiquitously distributed PC) mRNA levels (21) . Rats made hyperthyroid by daily injection of L-thyroxine (T 4 ) showed decreased anterior pituitary PC1, PC2, and PAM mRNA levels and increased PACE4 mRNA levels (6, 21) .
Thyroid hormone (triido-L-thyronine, T 3 ) regulates target gene expression by binding with nuclear thyroid hormone receptors (TRs). T 3 /TR mediates transcriptional regulation through interactions in the promoter region of target genes bearing consensus DNA sequences, referred to as thyroid hormone response element (TRE) (27) . Heterodimerization between TR and retinoid X receptor (RXR) usually augments the liganddependent stimulation or repression (27) . However, in a few TREs, such as the one in human type 1 deiodinase promoter, RXR-independent mechanisms are involved in thyroid hormone regulation (50) .
T 3 acts through TRs at the transcriptional level to regulate many genes such as TRH, thyroid stimulating hormone (TSH), growth hormone (GH), and ␣-myosin heavy chain (27) . We have previously shown that T 3 negatively regulates PC2 in the rat anterior pituitary and in GH3 cells and localized a region on the human PC2 promoter that contains putative negative TREs (nTREs) (30) . In this paper, we first studied the in vivo regulation of PC1 mRNA by thyroid status in rat pituitary. To address the mechanism of T 3 regulation of the PC1 gene, we used GH3 cells. This rat somatotroph cell line expressing endogenous TRs (14) has been widely used to study T 3 regulation of both endogenous (35) and exogenous genes (15) . We used hPC1 promoterluciferase constructs and electrophoretic mobility shift assays (EMSAs) to identify the region responsible for the negative regulation by T 3 . These studies provide a cellular mechanism for the regulation of pituitary PC1 levels by thyroid hormone.
MATERIALS AND METHODS
Northern blot analysis of pituitary PC1 mRNA from rats receiving PTU and T 3 . Adult male Sprague-Dawley rats weighing ϳ250 g were housed in a light-and temperaturecontrolled environment and were fed standard laboratory rat chow. Three groups of four animals each were treated as follows. In the control group, rats received drinking water for 2 wk, followed by daily intraperitoneal injection of vehicle for 3 days before being killed. In the hypothyroid group, PTU (0.05%) was added to the drinking water of the rats for 2 wk, and then the rats received daily intraperitoneal vehicle injection for 3 days. In the hyperthyroid group, PTU (0.05%) was added to the drinking water of the rats for 2 wk, and then the rats received daily intraperitoneal injection of T 3 (300 g/kg) for 3 days. Animals were then killed by CO 2 administration, and plasma was immediately collected from the neck veins. Plasma TSH was measured by RIA according to the manufacturer's instructions (Diagnostic Products, Torrance, CA). The anterior pituitary was separated from the neurointermediate lobe, and total RNA from individual anterior pituitaries was extracted by means of TRIzol (GIBCO BRL, Gaithersburg, MD). Five micrograms of total RNA were fractionated on a 1.2% denaturing agarose gel and transferred to a GeneScreen Plus hybridization transfer membrane (Du Pont NEN, Boston, MA). The pcDNA3.1(ϩ)/rPC1 construct used for generating the rat PC1 riboprobe was cloned from the BamH I and Bgl II fragment of pCD-BDP (rat PC1) (11) into the BamH I site of pcDNA3.1(ϩ) vector (Invitrogen, Carlsbad, CA) in reverse orientation. The construct was further cut by Nhe I to delete the 3Ј-end fragment and was self-ligated. Northern blots were carried out as described previously (34) . The protocol was conducted according to National Institutes of Health guidelines and was approved by the Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center.
Cell culture. GH3 cells (rat somatotroph cells) and JEG-3 cells (human choriocarcinoma cells) were obtained from the American Type Culture Collection (Rockville, MD) and were maintained at 37°C and 5% CO 2 in DMEM with 10% fetal bovine serum (FBS; GIBCO BRL) supplemented with 0.075% sodium bicarbonate, 50 IU/ml penicillin-streptomycin and 0.125 mg/ml Fungizone (amphotericin B; GIBCO BRL). CV-1 (African Green monkey kidney) cells were kindly provided by Dr. Phillip Koeffler (Cedars-Sinai Medical Center) and were grown in MEM supplemented with 10% FBS, 2 mM L-glutamine, 0.11 mg/ml sodium pyruvate, and nonessential amino acids.
Plasmid constructs and luciferase assays. The human PC1 (hPC1)-luciferase fusion gene expression plasmids were constructed by subcloning progressively truncated hPC1 promoter with 5Ј-end at Ϫ702, Ϫ82, and Ϫ18 bp relative to the transcription start site (TSS) into the polylinker region of the promoterless, luciferase-encoding pGL2-basic plasmid (Promega, Madison, WI). The 3Ј-end of all these constructs ended at position ϩ216 bp relative to the TSS. Smaller hPC1 promoter constructs, containing nucleotides from Ϫ82 to ϩ111 and from Ϫ82 to ϩ19 bp relative to TSS, were also cloned into the pGL2-basic plasmid and were used for transfection in GH3 cells. The human TRH (hTRH)-(31) and rat GH (rGH)-luciferase constructs were generated by subcloning the fragments from Ϫ900 to ϩ54 and Ϫ528 to ϩ65 bp relative to TSS, respectively, into the promoterless pA 3 -luciferase plasmid. The thymidine kinase-105 (TK-105)-luciferase construct used as a negative control was kindly provided by Dr. Lin Pei (Cedars-Sinai Medical Center). Full-length cDNAs of rat TR␣1, TR␣2, and TR␤1 were cloned into a pCDM8 expression vector (Invitrogen) and were used for cotransfection in JEG-3 and CV-1 cells.
Mutational analysis of the proximal promoter elements was done using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. The Ϫ82-to ϩ19-bp hPC1 promoter-luciferase construct was used as a template to generate a mutated construct. The oligonucleotide used was 5Ј-agggctggggctAAactcagccATTagaccgaagcg (upper-case letters indicate mutated nucleotides). Site-specific mutations were verified by sequencing.
GH3 cells were plated in growth medium in 6-well plates and allowed to adhere overnight. Cells were then placed in OPTI-MEM (GIBCO BRL) medium and overlaid with a mixture of DNA/cationic liposomes (lipofectamine, GIBCO BRL). Cells were incubated with DNA (3 g/well) for 6 h, and the medium was changed to DMEM serum-free medium for overnight incubation, followed by treatment of cells with either T 3 (10 Ϫ8 M), 9-cis-retinoic acid (9-cis-RA, 10 Ϫ7 M), or their combination for 24 h. Cells were then lysed in 25 mM Tris phosphate buffer (pH 7.8), 10 mM MgCl 2 , 0.1% BSA, 15% glycerol, 1% Triton X-100, and 1 mM EDTA. After centrifugation, 180 l of the cleared cell lysate were used for the luciferase assay. Luciferase activity was measured in a Berthold Lumat LB 9501 luminometer (Wallace, Gaithersburg, MD) in the presence of 0.8 mM ATP and 0.3 mM D-luciferin. Integrated light emission over 15 s was measured. All transfections were done in triplicate and were repeated at least three times.
To study the effects of TR isoforms on the T 3 regulation of PC1, JEG-3 and CV-1 cells were seeded overnight into 60-mm dishes, and the medium was changed 2-3 h before transfection by calcium phosphate precipitation. Three micrograms of hPC1 promoter-luciferase constructs, 0.5 g of TR, and 0.5 g of carrier plasmid were used for transfection. RSV 0 -␤-galactosidase (␤-gal) plasmid (1 g) was included in the transfection to measure transfection efficiency (32) . Six hours after transfection, the cells were incubated in the presence or absence of T 3 (10 Ϫ8 M) for 24 h. Luciferase activity was divided by ␤-gal activity to correct for transfection efficiency. All experiments were performed in duplicate plates, and each experiment was repeated three to five times.
Nuclear extract preparation and EMSAs. Nuclear extracts were prepared from GH3 cells according to Dignam et al. (7) . Protein concentrations in nuclear extracts were determined by Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). The region of hPC1 from Ϫ82 to ϩ19 bp relative to the TSS was generated by PCR. Double-stranded oligonucleotides corresponding to the hPC1 promoter sequences Ϫ10 to ϩ19 bp (O#1) and Ϫ37 to Ϫ18 bp (O#2) relative to the TSS were synthesized by GIBCO BRL and were radiolabeled using [␥-
32 P]ATP (6,000 Ci/mmol; NEN) and T 4 polynucleotide kinase (GIBCO BRL). EMSAs were performed as follows. GH3 nuclear proteins (0.5 g), purified TR␣1 (0.01-0.1 g, Santa Cruz Biotechnology, Santa Cruz, CA), or RXR␤ (2.0 g, BIOMOL Research Laboratories, Plymouth Meeting, PA) proteins were incubated for 10 min at room temperature in reaction buffer containing 20 mM HEPES buffer (pH 7.9), 50 mM KCl, 6.25 mM MgCl2, 0.5 mM EDTA, 10% glycerol, 0.5 mM dithiothreitol, and 2 g polydeoxyinosinic-deoxycytidylic acid as a nonspecific competitor. Subsequently, radiolabeled DNA probes were added, and the incubation was continued for another 30 min. For competition experiments, binding mixtures were incubated at room temperature with unlabeled double-stranded oligonucleotides for 10 min before the addition of the radiolabeled oligonucleotides. For antibody supershift experiment, specific antibodies were added to mixtures 10 min after the addition of the radiolabeled DNA probes. All specific antibodies were obtained from Santa Cruz Biotechnology. Protein-DNA complexes were analyzed on 5% nondenaturing polyacrylamide gels at 25°C in 0.5ϫ Tris borate/EDTA buffer and were visualized by autoradiography.
Statistical analysis. Statistical analyses were performed with the InStat 2.03 program using one-way ANOVA for multiple groups and post hoc Student's t-test (corrected using Dunnett's correction factor) for comparing treatment with control.
RESULTS
Regulation of pituitary PC1 mRNA in vivo by thyroid status. T 3 regulates many genes in the anterior lobe of pituitary. To study the regulation of pituitary PC1 by thyroid status, Sprague-Dawley rats were made hypothyroid by adding PTU to the drinking water for 2 wk. In another group of rats, thyroid hormone levels were then acutely elevated by intraperitoneal injection of T 3 3 days before the rats were killed. The hypothyroidism of PTU-treated rats was confirmed by increased TSH levels, and the hyperthyroidism of T 3 -treated rats was confirmed by decreased TSH levels (Fig. 1A) . The body weights of PTU-treated rats were significantly lower than those of the control animals (data not shown). As shown in Fig. 1B , administration of PTU resulted in an increase in both the 5.0-and 3.0-kb bands of PC1 mRNA in the anterior pituitary compared with control animals. T 3 supplementation for 3 days after PTU treatment decreased both bands of PC1 mRNA compared with the rats receiving PTU followed by vehicle. Quantitation demonstrated that PTU treatment resulted in a fivefold (P Ͻ 0.05) increase in the 3.0-kb band of PC1 mRNA compared with control. Moreover, T 3 supplementation after PTU treatment resulted in a 10-fold (P Ͻ 0.05) decrease in the 3.0-kb band compared with that of the rats receiving PTU followed by vehicle (Fig. 1C) . Similar results were obtained when Fig. 1 . Plasma thyroid-stimulating hormone (TSH) levels and Northern blot analysis of pituitary prohormone convertase (PC)1 mRNA in rats receiving 6-n-propyl-2-thiouracil (PTU) and triiodo-L-thyronine (T 3 ). Plasma TSH levels from control (CON), PTU-treated (PTU) and PTU plus T 3 -treated rats (PTU/T 3 ; A) representative Northern blot analysis of PC1 mRNA in anterior pituitary (B) of rats receiving PTU and T 3 treatment. Hybridization with cyclophilin (Cyclo) was used as an internal control to correct for differences in RNA loading. The quantitative result of the PC1 signal after correction for cyclophilin) is expressed as means Ϯ SE induction (n ϭ 4) over the control. *P Ͻ 0.05 vs. control; **P Ͻ 0.005 vs. group with PTU treatment; ***P Ͻ 0.0001 vs. control. E162 the 5.0-kb band of PC1 mRNA was quantitated (data not shown).
Regulation of hPC1 promoter by T 3 and 9-cis-RA.
To analyze whether the regulation of PC1 in rat anterior pituitary was due to the direct effect of thyroid hormone on PC1 gene expression, we analyzed the hPC1 promoter by transient transfection in GH3 cells. We used the hPC1 Ϫ971-bp promoter luciferase construct (33) . The TK-105 construct, the hTRH promoter from Ϫ900 to ϩ54 bp (32) , and the rGH promoter from Ϫ528 to ϩ65 bp, all cloned upstream of the luciferase reporter gene, were used as T 3 -responsive controls in GH3 cells. As shown in Fig. 2 , T 3 (10 Ϫ8 M) inhibited hPC1 promoter activity by 50% (P Ͻ 0.05). 9-cis-RA (10 Ϫ7 M) alone increased (2.5-fold, P Ͻ 0.05) hPC1 promoter activity, whereas addition of T 3 reversed the stimulation to the basal level [P ϭ nonsignificant (NS) vs. control, P Ͻ 0.05 vs. 9-cis-RA treatment]. Consistent with previous observations (23) , T 3 and 9-cis-RA treatment resulted in a two-and threefold stimulation of rGH promoter, respectively. The combination of 9-cis-RA and T 3 resulted in an additive effect in the rGH promoter. In contrast to hPC1 promoter, the hTRH promoter was not affected by 9-cis-RA alone (P ϭ NS), and the T 3 -mediated downregulation of hTRH promoter was not further affected by the presence of 9-cis-RA. In addition, the TK promoter was not affected by either 9-cis-RA, T 3 , or their combinations. Taken together, these results are similar to the results of T 3 and/or 9-cis-RA regulation on the hPC2 promoter (30) and suggest that 9-cis-RA positive and T 3 negative regulation are unique to these two members (PC1 and PC2) of the prohormone convertase family.
Deletion analysis of the hPC1 promoter in GH3 cells. To further analyze T 3 -mediated transcriptional regulation and characterize the putative TREs within the hPC1 promoter, we performed a series of transient transfection assays in GH3 cells with progressive 5Ј deletions of the hPC1 promoter. The results are expressed as luciferase activity in the presence and absence of T 3 and also as percent repression compared with the control cells (without T 3 ). As shown in Fig. 3 , all constructs tested containing the hPC1 promoter revealed similar T 3 -mediated suppression, which was 43-58% of the control (without T 3 ) and demonstrated statistically significant suppression. Further localization of the region on the hPC1 promoter responsible for the negative regulation by T 3 was achieved by deleting the 3Ј end of the construct to ϩ19 bp. Thus the minimal construct tested (Ϫ82 to ϩ19 bp) still exhibited both basal luciferase activity and downregulation by T 3 . This suggests that the nTREs are likely located near the TSS, and the sequence between Ϫ82 and ϩ19 bp is sufficient to mediate the T 3 -inhibitory effect on the hPC1 promoter. Similar inhibition by T 3 was obtained using the hTRH promoter (32) . In contrast, T 3 caused a twofold stimulation of rGH promoter, as previously reported (4) . No significant influence of T 3 on the control TK-or pGL2-basic luciferase promoter activity was observed, and the activity of pGL2 basic plasmid was minimal.
TR isoforms on the T 3 -repressive effect of hPC1 promoter in JEG-3 and CV-1 cells. To study whether T 3 -/TR-mediated repression of hPC1 promoter activity in GH3 cells is TR isoform specific, we performed cotransfection experiments with the use of JEG-3 and CV-1 cells, both of which are known to express minimal amounts of endogenous TRs (40) . Successful transfection of the TR isoforms was assessed in both cell lines by showing that T 3 stimulated the GH gene and suppressed the TRH gene (data not shown). As shown in Fig. 4 , cotransfected TR was required for T 3 -mediated Fig. 3 . Deletion analysis to localize the putative thyroid hormone response elements in hPC1 promoter. Different hPC1 promoter constructs were transfected into GH3 cells and incubated in the presence or absence of T 3 (10 Ϫ8 M) for 24 h and then harvested for luciferase (Luc) assay. Results are expressed as means Ϯ SE of luciferase activity with and without T 3 from a representative experiment. The experiment was repeated on 3 independent occasions. *P Ͻ 0.05 vs. control for the 3 independent experiments. Fig. 2 . Effect of T 3 and 9-cis-retinoic acid (9-cis-RA) on human PC1 (hPC1) promoter activity. GH3 cells were transiently transfected with hPC1-luciferase (Ϫ701 to ϩ216 bp), rat GH (rGH)-luciferase, human thyrotropin-releasing hormone (hTRH)-luciferase and thymidine kinase (TK)-luciferase constructs using DNA cationic/liposomes method. After transfection and serum starvation, the cells were treated with either T 3 (10 Ϫ8 M), 9-cis-RA (10 Ϫ7 M), or their combinations for 24 h. Cells were then harvested for luciferase assay as described. Results are expressed as means Ϯ SE of luciferase activity from 3 independent experiments. *P Ͻ 0.05 vs. control.
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repression of the hPC1 promoter in the two cell lines tested. However, unlike the results from hTRH (32) and mouse TRH (40) promoters, cotransfection of TR alone did not stimulate basal hPC1 promoter activity. Addition of 10 nM T 3 in the cells cotransfected with either TR␣1 or TR␤1 resulted in a 50-70% reduction in luciferase activity, with similar inhibition in CV-1 and JEG-3 cells. In contrast, addition of 10 nM T 3 to the cells cotransfected with TR␣2 [the TR isoform lacking ligand binding capacity (27) ] alone did not affect the hPC1 promoter activity. These results suggest that T 3 -mediated hPC1 gene expression is dependent on the presence of functional TRs and that there is no TR␣1 or TR␤1 isoform preference in the regulation of hPC1 promoter in the transient transfection system used in our study.
Binding of purified TR␣1 and RXR␤ proteins to the hPC1 Ϫ82-to ϩ19-bp fragment in EMSAs. To examine whether TR binding sites reside within the functionally defined fragment from Ϫ82 to ϩ19 bp of hPC1 promoter, EMSAs were carried out using purified recombinant TR␣1 and RXR␤ proteins. Binding was assessed with the hPC1 promoter (from Ϫ82 to ϩ19 bp) and the direct-repeat 4 (DR4) element, which was used as a positive control (12) . As shown in Fig. 5 , purified TR protein bound to DR4 (A) and hPC1 (B) as two bands corresponding to TR monomer (M) and homodimer (HOD). The binding was specific as it was competed by addition of 100-fold molar excess of unlabeled identical oligonucleotides [ TR/RXR heterodimer band (HED) was detected for both DR4 and hPC1 (lane 6). This band has slightly faster mobility than TR homodimer due to the smaller molecular mass of purified RXR (51 kDa) than TR (73 kDa) protein. Interestingly, a large-sized multimer band of TR/RXR was observed by use of the hPC1 fragment (Fig. 5B, lane 6) . The multimer-(for hPC1) and heterodimer-containing (for both DR4 and hPC1) complexes were supershifted by the addition of anti-TR and anti-RXR antibody (lanes 7 and 8, respectively) , confirming the identity of the binding complexes.
EMSAs with two oligonucleotides selected from Ϫ82 to ϩ19 bp of the hPC1 promoter. To further characterize the TR binding region of the hPC1 promoter, two oligonucleotides containing TRE-like sequences were selected (Fig. 6A ) from Ϫ10 to ϩ19 bp (O#1) and from Ϫ37 to Ϫ18 bp (O#2) from the Ϫ82-to ϩ19-bp region of the hPC1 promoter. O#1 contained one putative TRE half-site that matches six of six nucleotides of the hexameric consensus TRE half-sites [(A/G)GGT-(C/G)A], one putative TRE half-site matching five of six nucleotides of the hexameric consensus, and two putative TRE half-sites matching four of six nucleotides of the hexameric consensus; O#2 contained one putative TRE half-site matching five of six nucleotides of the consensus TRE. EMSAs were performed with these probes by use of increasing amounts of purified TR␣1. As indicated in Fig. 6B , only minimal binding was detected using O#2, which contains a single TRE-like half-site (AGGTAA) arranged in reverse orientation (from 3Ј to 5Ј). The lack of binding of this oligonucleotide (Ϫ37 to Ϫ18 bp) is not surprising considering that the Ϫ18-to ϩ216-bp construct did not show a decline in inhibition by T 3 compared with the Ϫ82-to ϩ216-bp construct. In contrast, both monomer and homodimer binding were observed by means of O#1 with increasing intensity of binding when increasing amounts of TR␣1 protein were included (Fig. 6B) .
It has been demonstrated that specific nuclear proteins can enhance the TR binding to certain DNA elements (24) . To confirm that the binding of O#1 from hPC1 promoter observed above with purified TR␣1 protein reflects the binding within GH3 cells, we performed EMSAs with double-stranded, unlabeled O#1 and O#2 to compete for the binding of GH3 cell nuclear extracts to the DR4 probe. As shown in Fig. 6C , a single binding band (indicated by a solid arrow) was observed when the DR4 probe was incubated with GH3 nuclear Fig. 6 . Binding of two oligonucleotides selected from Ϫ10 to ϩ19 bp (O#1) and Ϫ37 to Ϫ18 bp (O#2) of the hPC1 promoter to purified TR␣1 and the ability of those oligonucleotides to compete with labeled DR4 for binding to GH3 nuclear extracts. A: sequences of two oligonucleotides (O#1 and O#2) selected from hPC1 promoter. B: probes were incubated with increasing amounts of TR␣1 protein (0, 0.01, 0.04, 1.0 g). C: DR4 probe was incubated with GH3 nuclear extract, and binding of GH3 nuclear protein to DR4 was competed with increasing amounts of O#1 and O#2. Lane . These results suggest the specificity of TR proteins in GH3 nuclear extract binding to DR4 element. When excess of the two hPC1 oligonucleotides (200-, 20-, 5-fold excess) competing for DR4 binding to GH3 nuclear extracts was examined, the addition of O#1, but not O#2, efficiently inhibited the binding, the 200-fold excess of O#1 completely abolishing the binding (lane 6). Taken together, these results suggest that the binding of O#1 to purified TR␣1 is likely to reflect the binding occurring within GH3 cells, and the region between Ϫ10 and ϩ19 bp on hPC1 promoter is likely responsible for the T 3 negative regulation of the hPC1 promoter.
EMSAs using wild-type and mutant oligonucleotides with TR␣1 and RXR␤ proteins. To further investigate whether TR/RXR interaction occurred in O#1, EMSAs were carried out using purified TR␣1 and RXR␤ proteins with wild-type (WT) and mutant (Mut) oligonucleotides as probes (Fig. 7A ). As indicated in Fig. 7B , when higher amounts of TR␣1 were added to the reactions, both TR monomer and homodimer were detected (lane 2) with O#1. The addition of T 3 diminished the homodimer binding (lane 3) more than the monomer binding, which is consistent with the observation on other consensus TRE sequences (9) . The addition of TR␣1 antibody supershifted the binding (lane 4), which suggests the specificity of the TR␣1 and O#1 interaction. In the lane (lane 5) with a low (0.01 g) amount of TR␣1, faint TR homodimer with a larger amount of monomer binding was detected. RXR itself did not bind to O#1 (lane 6). Interestingly, intense TR/RXR heterodimer and multimer binding was detected (lane 7) using O#1. The addition of TR antibody (lane 9) and to a lesser extent, T 3 (lane 8), reduced the intensity of the heterodimer-and multimer-containing complexes. The T 3 suppression of the hPC1 heterodimerization is unusual compared with previous reports (53) . These results indicated that not only the TR monomer and homodimer, but also TR/RXR heterodimer and multimer, can be formed with the O#1. In contrast to WT O#1, Mut O#1 (Fig. 7C ) lost homodimer binding and exhibited decreased monomer binding (Fig. 7C, lanes 2  and 5) . When TR␣1 and RXR were added to the reactions, heterodimer binding, but not multimer binding, was observed (Fig. 7C, lane 7) .
Mutation analysis of putative nTRE on the hPC1 promoter. To characterize the functional role of these novel, putative nTREs on the hPC1 promoter, transient transfection analysis in GH3 cells with the WT and Mut construct (changing the central two and three nucleotides of two putative nTREs) (see Fig. 7A ) constructs from the Ϫ82-to ϩ19-bp hPC1 promoter was performed, and the effect of T 3 was measured. As shown in Fig. 7D , T 3 treatment resulted in a 50% reduction of WT PC1 promoter-luciferase activity, as anticipated. When the Mut construct was tested, the T 3 downregulation of hPC1 promoter activity was only partially (33%) abolished . These results suggest that the T 3 inhibitory effect may involve more than two TRE-like half-sites, which is supported by the presence of multimer binding using this region in the EMSA assay (Fig. 7B, lane 7) .
DISCUSSION
The effects of thyroid hormone are protean. In the pituitary, thyroid hormone directly or indirectly regulates gene expression in all cell types (45, 46) . The prohormone convertases, including PC1, are important processing enzymes that determine the ratios of many inactive prohormone precursors to active hormones (33, 43) . In this study, we demonstrate that changes in thyroid status alter anterior pituitary PC1 mRNA levels and that this regulation is due to the interaction between T 3 and TR with nTREs in the hPC1 promoter.
Stimulation of PC1 mRNA by intracellular protein kinase C and protein kinase A pathways has been demonstrated (17, 18, 51) . The promoter region of hPC1 contains one cAMP-response element (CRE) consensus sequence (TGACGTCA) and one CRE-like sequence (TGACGTGT) at positions Ϫ77 to Ϫ70 bp and Ϫ49 to Ϫ42 bp, respectively. In addition to the CREs, one putative Sp1 site (CCGCCC) is located at position ϩ42 to ϩ47 bp relative to the major TSS. Other elements, such as TREs, have not been characterized. In our study, deletional analysis of hPC1 promoter constructs in transient transfection assay coupled with EMSAs demonstrate that the region from Ϫ18 to ϩ19 bp of the hPC1 promoter is likely responsible for the negative regulation by T 3 . This region is near the TSS, similar to the observation for nTREs described by others (40) . Transcriptional repression by T 3 can occur through several mechanisms, including 1) binding of TRs to specific nTREs near TSS to sterically interfere with components of transcription initiation machinery (37) and 2) competitive binding of TREs to other transactivation factors, in particular the Sp1 (52) and activator protein 1 (28) complex, and the estrogen receptor (41) . Heterodimerization of active proteins with inactive forms and competition for limiting transactivation proteins may also occur (32, 47) . Moreover, complex interactions may involve more than one of these principles on "composite" DNA response elements. The hPC1 promoter lacks canonical TATA or CAAT boxes (19, 36) . The potential binding sites for transcriptional factors, such as Sp1, activating transcription factor, and CRE binding protein are located beyond the Ϫ18 to ϩ19 bp of hPC1 promoter. These findings suggest that nuclear factors other than those listed above may be involved in T 3 suppression of the hPC1 promoter.
RXR has been shown to heterodimerize with TR to increase TR/DNA interactions (12) . A number of studies have demonstrated that such heterodimerization can augment T 3 -mediated gene regulation (9) . However, the magnitude of the augmentation varies significantly, especially when different cell lines are used. In our study, both 9-cis-RA and T 3 stimulated rGH promoter, and the combination of T 3 and 9-cis-RA exerted additive effects on this promoter in GH3 cells, which is consistent with the previous analysis (54) . In contrast to the rGH promoter, basal hTRH promoter luciferase activity was not affected by 9-cis-RA, and the T 3 -mediated inhibitory effect on the hTRH promoter was not altered by the 9-cis-RA. Interestingly, 9-cis-RA treatment also increased hPC1 promoter activity and the addition of T 3 reversed that stimulation to basal level, similar to our studies with 9-cis-RA and the hPC2 promoter (30) . The effects on the hPC1 promoter could represent cumulative effects of RXR-mediated stimulation and TR-mediated repression. Alternatively, TR and RXR may competitively bind with the same DNA sequences located at the Ϫ18 to ϩ19 bp of hPC1. However, the lack of specific RXR binding to the Ϫ18 to ϩ19 bp of hPC1 promoter in the EMSA experiments (Fig. 7A ) argues against these hypotheses. Moreover, when the hPC1-971 promoter was transfected into JEG-3 cells (which express high levels of endogenous RXR␤), promoter activity was not significantly increased by 9-cis-RA treatment in the conditions with or without cotransfection of TR (data not shown). These results suggest that other cell type-specific nuclear factors in addition to TR/RXR may be required for either 9-cis-RA and/or T 3 -mediated regulation.
Multiple TR isoforms are derived from two distinctive genes by alternative promoter usage and alternative splicing of primary gene products (27, 37) . TR isoform specificity in regulation of target gene expression has been demonstrated in myelin basic protein genes (26) and in the rat TRH gene (29) . In the present study, we did not observe any significant functional differences between TR␣1 and TR␤1 isoforms in the hPC1 promoter in either CV-1 or JEG-3 cells. These results were consistent with previous findings in human and mouse TRH genes (8, 40) and the hPC2 promoter (30) . The lack of functional differences among TR␣1 and TR␤1 isoforms in our study may be due to the different nTREs in the different promoters and the levels of endogenous TR, RXR, and other cell typespecific transcriptional factors. Alternatively, the overexpression of TR in transient transfection assays may not reflect the fine-tune regulation that occurs in vivo. In contrast to some studies on T 3 negatively regulated genes (8, 40) , our study showed that cotransfection of either TR␣1 or TR␤1 alone in both CV-1 and JEG-3 cells did not affect the basal PC1 promoter activity, but addition of T 3 resulted in suppression. These results were supported by the study of the nTRE of hPC2 promoter (30) and epithelial growth factor receptor promoter (52) . We postulate that, taken together, some untested or unidentified transcriptional factor may interact with both TR and RXR to mediate T 3 regulation on hPC1 promoter in a manner similar to the hPC2 promoter.
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Positive TREs generally are composed of paired hexameric half-sites [(A/G)GGT(C/G)A] (27, 37) . In addition, immediate flanking sequences of hexameric halfsites may also modulate TR-DNA interactions (50) . The configuration of promoters negatively regulated by thyroid hormone through nTREs is largely unknown. Most nTREs identified so far, such as those in mouse and human TRH (29, 40) , rat sodium, potassium ATPase (48), TSH␤ subunit and glycoprotein-␣ subunit (5), exhibit variable half-site sequences, which may or may not contain consensus TRE sequences. EMSAs using purified TR␣1 and RXR proteins and GH3 nuclear extracts led us to further localize the regions between the Ϫ10 and ϩ19 bp of hPC1 promoter containing putative nTREs. It is not surprising that this region is able to form a TR␣1/RXR heterodimer and multimer, because multiple TRE-like hexameric sequences arranged presumably as direct repeat and inverted palindrome are present (Fig. 6A) . EMSAs with mutant oligonucleotides, in which the core of two putative nTREs were mutated (Fig. 7A) , revealed diminished TR monomer and homodimer binding (Fig.  7C, lanes 2 and 5) . Most interestingly, the mutant oligonucleotides still preserved TR/RXR heterodimer but not multimer binding. Because of the diversity of TREs identified in different genes, we hypothesize that the region between Ϫ10 and ϩ19 bp of hPC1 promoter contains multiple TRE-like half-sites, which function in concert to mediate T 3 regulation. Transient transfection in GH3 cells supports this hypothesis, as the construct with indicated point mutations exhibited a reduced, but not abolished, effect of T 3 . This indicates that the negative effects of T 3 are likely mediated through a series of partial nTREs in the region between Ϫ10 and ϩ19 bp, and the mutated nTREs partially contribute to the cumulative effect of T 3 .
Finally, in this paper, our in vivo results of rat anterior pituitary PC1 mRNA regulated by thyroid status confirms the findings of Day et al. (6) and are similar to the results of rat anterior pituitary PC2 mRNA regulated by thyroid status (30) . Hypothyroidism induced a more profound stimulation of PC1 (this paper) than of PC2 mRNA (30) in the anterior pituitary. Additionally, T 3 intraperitoneal injection for 3 days after prolonged PTU treatment decreased PC1 mRNA, whereas T 3 administration (after PTU treatment) only returned PC2 mRNA to the control levels. These results indicate that PC1 mRNA is more susceptible to alterations of thyroid hormone than PC2 is. Examining the T 3 -responsive regions on the hPC1 and hPC2 promoter along with the in vivo observations, we hypothesize that the putative nTREs on the hPC1 promoter interact more strongly with TR/RXR and other nuclear proteins than the nTREs on the hPC2 promoter.
Thyroid hormones are essential for growth and development. Thyroid hormone also exerts specific effects on several organ systems, including cardiovascular, reproductive, central, and peripheral nervous systems (13) . PC1 and PC2 process a wide variety of central and peripheral prohormones. In the anterior pituitary, PC1 and PC2 are found in corticotrophs, thyrotrophs, and gonadotrophs (49) . In the corticotroph, PC1 and PC2 have clearly been shown to process POMC to ACTH (42) . They may also process the precursors to substance P, neuropeptide Y, and vasoactive intestinal peptide, hormones found to be increased in the anterior pituitary of hypothyroid rodents (1, 22, 25) . The simultaneous alterations of both PC1 and PC2 by thyroid hormone (compared with the alterations in either PC1 or PC2 alone in the patient deficient in PC1 and in mice with a knockout of PC2) may mediate more profound alterations in the levels of many hormones.
